Clinical trial NCT05703009: Effects of Sacrosidase and Placebo in Subjects With Fructan Intolerance
Official title: A Double-Blind, Placebo-Controlled, Crossover Study of Sacrosidase for the Treatment of Subjects With Fructan Intolerance
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Fructan Intolerance
Lead sponsor: QOL Medical, LLC
Sponsor class: INDUSTRY
First posted: 2023-01-27
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: SSDXA-14 is a Phase 2 (feasibility/pilot) double-blind, placebo-controlled, crossover study to evaluate the efficacy and safety of sacrosidase and placebo in 25 subjects objectively diagnosed with fructan intolerance.

Detailed description: This Phase 2 study will evaluate the efficacy and safety of sacrosidase and placebo in male and female subjects aged 18 years or older objectively diagnosed with fructan intolerance via fructan breath test within 6 months prior to informed consent and are negative for inflammatory bowel disease or low-grade GI bacterial infection, detected by fecal calprotectin test, celiac disease, detected by serology for anti-gluten protein antibodies, congenital sucrase-isomaltase deficiency (CSID), detected by sucrose hydrogen-methane breath test, and have a negative result for abnormal uncontrolled thyroid function, detected by the standard TSH blood test. This study will consist of a Screening Visit, Baseline Period, Treatment Period 1, Washout Period, and Treatment Period 2. Subjects will be required to attend 5 clinic visits during study participation. Subjects will be randomized in a 1:1 fashion to either receive sacrosidase or placebo during Treatment Period 1. Following a 7-day Washout Period, subjects will receive their crossover study medication for Treatment Period 2. Subjects will take their assigned study medication for 7 days during each Treatment Period.

Eligibility criteria: Inclusion Criteria:

* Ability to comprehend and provide a signed and dated informed consent form
* Stated willingness to comply with all study procedures and attend all scheduled clinic visits, and continue participation for the duration of the study
* Ability to self-administer oral medication and willingness to adhere to the medication regimen
* Male or non-pregnant, non-lactating female, at least 18 years of age
* Sexually active women of childbearing potential must agree to use at least one reliable method of birth control while participating in the study
* Presence of fructan intolerance as determined by a positive result on a FBT within the last 6 months
* Subjects who are lactose intolerant agree to eliminate all lactose from their diet during the study
* Stated willingness to discontinue any medications to resolve GI symptoms (digestive enzymes, antacids, proton pump inhibitors, histamine-2 blockers, promotility agents, or anti-diarrheal agents, etc.), per the investigator's discretion.
* Stated willingness to discontinue any over the counter or prescribed oral nonsteroidal anti-inflammatory drugs (NSAIDs) during the study
* Per the discretion of the investigator, absence of any GI disorder other than a diagnosis of fructan intolerance

Exclusion Criteria:

* History of inflammatory bowel disease or active low-grade GI bacterial infection, as diagnosed by the presence of fecal calprotectin
* History of celiac disease, as diagnosed by serology testing for anti-gluten protein antibodies
* History of CSID, as diagnosed by the sucrose hydrogen-methane breath test,
* Abnormal uncontrolled thyroid function, detected by abnormal TSH level in the blood
* Per the discretion of the investigator, history of a serious physical or mental disorder
* BMI greater than 30 kg/m2
* History of diabetes
* History of hypersensitivity to yeast, yeast products, glycerin (glycerol), or papain

Primary outcomes:
measure: Change in incidence and severity of gastrointestinal symptoms in subjects with fructan intolerance treated with sacrosidase and placebo
timeFrame: Up to 7 weeks
Secondary outcomes:
measure: Change in incidence and severity of abdominal pain in subjects with fructan intolerance treated with sacrosidase and placebo
timeFrame: Up to 7 weeks
measure: Assess the safety and tolerability of sacrosidase compared to placebo in subjects with fructan intolerance
timeFrame: Up to 1 year
Other outcomes:
Locations:
city: Boston
country: United States
facility: Boston Specialists
state: Massachusetts
Study officials:
affiliation: QOL Medical, LLC
name: Weng Tao, M.D., Ph. D
role: PRINCIPAL_INVESTIGATOR
References: